A study evaluating safety and efficacy of Ceftolozane/tazobactam against extensively drug-resistant Pseudomonas aeruginosa in patients with skin and soft tissue infections (SSTI) and osteomyelitis.

At a glance
Trial Overview
Trial Details
- Other Details
- Related Drugs
Interventions
Results
- Publications
Authors
Trial History
References

X

Trial Profile

A study evaluating safety and efficacy of Ceftolozane/tazobactam against extensively drug-resistant Pseudomonas aeruginosa in patients with skin and soft tissue infections (SSTI) and osteomyelitis.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 11 May 2017

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ceftolozane/tazobactam (Primary)
Indications Osteomyelitis; Skin and soft tissue infections
Focus Adverse reactions; Therapeutic Use

Most Recent Events

11 May 2017 New trial record
25 Apr 2017 Results presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com